Therapeutic Targeting of Hepatic Macrophages

Hilde Nijland, Ruchi Bansal*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

37 Downloads (Pure)


Purpose of ReviewThis review outlines the current knowledge about hepatic macrophages and provides an overview of therapeutic approaches to target hepatic macrophages for the treatment of liver diseases.Recent FindingsIn recent years, it has been increasingly recognized that hepatic macrophages (resident macrophages, Kupffer cells, or circulating bone marrow monocyte-derived macrophages) are implicated in liver homeostasis as well as in disease progression and resolution. More recently, different populations of hepatic macrophages with distinct phenotypes and functions have been identified that have shown to play distinct roles in the pathogenesis of various acute and chronic liver diseases. The understanding of the role of hepatic macrophages in initiation, progression, and resolution of liver diseases has given rise to the development of therapeutics that can target different phenotypes of hepatic macrophages. Innovative strategies comprises of microRNA (miRNA), small interfering RNA (siRNA), therapeutic proteins, and small-molecule inhibitors.SummaryEvidence from recent in vitro and in vivo studies support the fact that hepatic macrophages can be efficiently targeted using miRNA/siRNA-based approaches, protein-based approaches, and small-molecule inhibitors for the treatment of liver diseases. However, more in-depth understanding underlying the roles of distinct macrophage phenotypes in different liver diseases is required for the translation of novel targeted therapeutics to the clinic.
Original languageEnglish
Pages (from-to)113-120
JournalCurrent Tissue Microenvironment Reports
Publication statusPublished - 24 Sept 2020


  • UT-Hybrid-D


Dive into the research topics of 'Therapeutic Targeting of Hepatic Macrophages'. Together they form a unique fingerprint.

Cite this